These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19153776)

  • 1. Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker.
    Miura K; Sekine T; Iida A; Takahashi K; Igarashi T
    Pediatr Nephrol; 2009 Jun; 24(6):1235-8. PubMed ID: 19153776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of eight patients with congenital nephrogenic diabetes insipidus.
    Mizuno H; Sugiyama Y; Ohro Y; Imamine H; Kobayashi M; Sasaki S; Uchida S; Togari H
    Endocrine; 2004 Jun; 24(1):55-9. PubMed ID: 15249704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2Y12 Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus.
    Zhang Y; Peti-Peterdi J; Müller CE; Carlson NG; Baqi Y; Strasburg DL; Heiney KM; Villanueva K; Kohan DE; Kishore BK
    J Am Soc Nephrol; 2015 Dec; 26(12):2978-87. PubMed ID: 25855780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of partial nephrogenic diabetes insipidus with thiazide and desmopressin.
    Mizuno H; Fujimoto S; Sugiyama Y; Kobayashi M; Ohro Y; Uchida S; Sasaki S; Togari H
    Horm Res; 2003; 59(6):297-300. PubMed ID: 12784095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Children's toxicology from bench to bed--Drug-induced renal injury (1): The toxic effects of ARB/ACEI on fetal kidney development.
    Sekine T; Miura K; Takahashi K; Igarashi T
    J Toxicol Sci; 2009; 34 Suppl 2():SP245-50. PubMed ID: 19571476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review.
    Bullo M; Tschumi S; Bucher BS; Bianchetti MG; Simonetti GD
    Hypertension; 2012 Aug; 60(2):444-50. PubMed ID: 22753220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
    Mayyas F; Bataineh W; Jarab A
    Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
    Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
    J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
    Shoda J; Kanno Y; Suzuki H
    Intern Med; 2006; 45(4):193-8. PubMed ID: 16543688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin system blockade and contrast-induced renal toxicity.
    Saudan P; Muller H; Feraille E; Martin PY; Mach F
    J Nephrol; 2008; 21(5):681-5. PubMed ID: 18949722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of urinary concentration in nephrogenic diabetes insipidus.
    McConnell RF; Lorentz WB; Berger M; Smith EH; Carvajal HF; Travis LB
    Pediatr Res; 1977 Jan; 11(1 Pt 1):33-6. PubMed ID: 188007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
    Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D
    Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability.
    de Groot T; Doornebal J; Christensen BM; Cockx S; Sinke AP; Baumgarten R; Bedford JJ; Walker RJ; Wetzels JFM; Deen PMT
    Am J Physiol Renal Physiol; 2017 Sep; 313(3):F669-F676. PubMed ID: 28615247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.